- Home
- BETR vs NBTX Comparison
BETR vs NBTX Comparison
Compare BETR & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- NBTX
- Stock Information
- Founded
- BETR 2014
- NBTX 2003
- Country
- BETR United States
- NBTX France
- Employees
- BETR N/A
- NBTX N/A
- Industry
- BETR Finance: Consumer Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- BETR Finance
- NBTX Health Care
- Exchange
- BETR Nasdaq
- NBTX Nasdaq
- Market Cap
- BETR 203.4M
- NBTX 211.9M
- IPO Year
- BETR N/A
- NBTX 2020
- Fundamental
- Price
- BETR $13.35
- NBTX $6.67
- Analyst Decision
- BETR
- NBTX Strong Buy
- Analyst Count
- BETR 0
- NBTX 1
- Target Price
- BETR N/A
- NBTX $8.00
- AVG Volume (30 Days)
- BETR 34.7K
- NBTX 7.5K
- Earning Date
- BETR 08-07-2025
- NBTX 09-17-2025
- Dividend Yield
- BETR N/A
- NBTX N/A
- EPS Growth
- BETR N/A
- NBTX N/A
- EPS
- BETR N/A
- NBTX N/A
- Revenue
- BETR $118,790,000.00
- NBTX N/A
- Revenue This Year
- BETR $60.22
- NBTX N/A
- Revenue Next Year
- BETR $69.03
- NBTX $74.67
- P/E Ratio
- BETR N/A
- NBTX N/A
- Revenue Growth
- BETR 56.38
- NBTX N/A
- 52 Week Low
- BETR $7.71
- NBTX $2.76
- 52 Week High
- BETR $25.90
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- BETR 48.76
- NBTX 66.43
- Support Level
- BETR $12.57
- NBTX $6.49
- Resistance Level
- BETR $14.58
- NBTX $7.15
- Average True Range (ATR)
- BETR 0.76
- NBTX 0.36
- MACD
- BETR -0.09
- NBTX 0.11
- Stochastic Oscillator
- BETR 29.43
- NBTX 73.88
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.